TY - JOUR T1 - Altered neutrophil phenotype and function in non-ICU hospitalised COVID-19 patients correlated with disease severity JF - medRxiv DO - 10.1101/2021.06.08.21258535 SP - 2021.06.08.21258535 AU - KBR Belchamber AU - OS Thein AU - J Hazeldine AU - FS Grudzinska AU - MJ Hughes AU - AE Jasper AU - KP Yip AU - E Sapey AU - D Parekh AU - DR Thickett AU - A Scott Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/08/2021.06.08.21258535.abstract N2 - Rational Infection with the SARS-CoV2 virus is associated with elevated neutrophil counts. Evidence of neutrophil dysfunction in COVID-19 is based predominantly on transcriptomics or single functional assays. Cell functions are interwoven pathways, and so understanding the effect of COVID-19 across the spectrum of neutrophil function may identify tractable therapeutic targets.Objectives Examine neutrophil phenotype and functional capacity in COVID-19 patients versus age-matched controls (AMC)Methods Isolated neutrophils from 41 hospitalised, non-ICU COVID-19 patients and 23 AMC underwent ex vivo analyses for migration, bacterial phagocytosis, ROS generation, NET formation (NETosis) and cell surface receptor expression. DNAse 1 activity was measured, alongside circulating levels of cfDNA, MPO, VEGF, IL-6 and sTNFRI. All measurements were correlated to clinical outcome. Serial sampling on day 3-5 post hospitalisation were also measured.Results Compared to AMC, COVID-19 neutrophils demonstrated elevated transmigration (p=0.0397) and NETosis (p=0.0366), but impaired phagocytosis (p=0.0236) associated with impaired ROS generation (p<0.0001). Surface expression of CD54 (p<0.0001) and CD11c (p=0.0008) was significantly increased and CD11b significantly decreased (p=0.0229) on COVID-19 patient neutrophils. COVID-19 patients showed increased systemic markers of NETosis including increased cfDNA (p=0.0153) and impaired DNAse activity (p<0.0.001). MPO (p<0.0001), VEGF (p<0.0001), TNFRI (p<0.0001) and IL-6 (p=0.009) were elevated in COVID-19, which positively correlated with disease severity by 4C score.Conclusion COVID-19 is associated with neutrophil dysfunction across all main effector functions, with altered phenotype, elevated migration, impaired antimicrobial responses and elevated NETosis. These changes represent a clear mechanism for tissue damage and highlight that targeting neutrophil function may help modulate COVID-19 severity.Competing Interest StatementGrant funding for research but no other competing interest: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support from Medical Research Council for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementOST/DT/DP; Birmingham Health partners, KBRB/ES; Alpha One Foundation (617303), JH; National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, ES/KYP; British Lung Foundation (PPRG16), DT/AS/ES/FSG; Dunhill trust (RTF1906\86), ES; Health Data Research-UK, DT/DP; Health Technology Assessment, DT/AS/ES; Health Technology Assessment (NIHR129593), DT/AS/ES; Medical Research Council (MR/L002736/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:19/WA/0299 and 20/WA/0092 approved by the West Midlands - Solihull research ethics committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNone ER -